SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.

Shenzhen Kangtai Biological Products Co., Ltd.

300601

CNE100002Q33

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-22 pm EDT			5-day change	1st Jan Change
19.88 ^CNY	-1.14%		-3.26%	-26.78%

Jan. 10	Kangtai Biological Forecasts Swing to Profit in 2023	MT
2023	Shenzhen Kangtai Biological Products Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	CI

Shenzhen Kangtai Biological Products Co., Ltd.(XSEC:300601) added to FTSE All-World Index

June 24, 2019 at 12:00 am EDT

Shenzhen Kangtai Biological Products Co., Ltd.(XSEC:300601) added to FTSE All-World Index (USD)

Latest news about Shenzhen Kangtai Biological Products Co., Ltd.

Kangtai Biological Forecasts Swing to Profit in 2023	Jan. 10	MT
Shenzhen Kangtai Biological Products Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Kangtai Signs Deal to Distribute Varicella Vaccine in Pakistan, India	23-09-20	MT
Shenzhen Kangtai Biological Products Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-25	CI
Kangtai Biological Partners With Indian Drugmaker to Distribute Pneumococcal Vaccine	23-05-31	MT
Shenzhen Kangtai Biological Products Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-23	CI
Tranche Update on Shenzhen Kangtai Biological Products Co., Ltd.'s Equity Buyback Plan announced on October 12, 2022.	23-03-15	CI
Shenzhen Kangtai Biological Products Co., Ltd.'s Equity Buyback announced on October 12, 2022 has closed with 3,581,600 shares, representing 0.32% for CNY 120.97 million.	23-03-12	CI
Shenzhen Kangtai Biological sees 2022 net loss on weaker COVID shot demand	23-01-10	RE
Tranche Update on Shenzhen Kangtai Biological Products Co., Ltd.'s Equity Buyback Plan announced on October 12, 2022.	23-01-03	CI
Shares in Chinese Pharma Companies Decline Amid Drop in Vaccination Rates	22-12-29	MT
Shenzhen Kangtai Biological Products Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI
Tranche Update on Shenzhen Kangtai Biological Products Co., Ltd.'s Equity Buyback Plan announced on October 12, 2022.	22-10-12	CI
Shenzhen Kangtai Biological Products Co., Ltd. commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on September 14, 2022.	22-10-12	CI
China's CanSinoBIO H1 revenue drops on weaker COVID shot demand	22-08-28	RE
UBS Adjusts Shenzhen Kangtai Biological Products’ Price Target to 66 Yuan From 72.50 Yuan, Keeps at Buy	22-08-22	MT
Shenzhen Kangtai Biological Products Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-18	CI
Shenzhen Kangtai Biological Products Co., Ltd. authorizes a Buyback Plan.	22-08-17	CI
Kangtai Biological Sees Up to 70% Profit Slump in H1	22-07-25	MT
UBS Adjusts Shenzhen Kangtai Biological Products' Price Target to 116 Yuan From 125 Yuan, Keeps at Buy	22-05-06	MT
Kangtai Biological’s 2021 Profit Surges 86% on Robust Sales	22-04-28	MT
Shenzhen Kangtai Biological Products Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-27	CI
Kangtai Biological’s Q1 Profit Seen Soaring 11-Fold on Strong Sales	22-04-14	MT
Shenzhen Kangtai Biological Products Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-13	CI
Shenzhen Kangtai Biological Products Co., Ltd Signs Framework Agreement with Phil.PharmaWealth Inc	22-03-21	CI

Chart Shenzhen Kangtai Biological Products Co., Ltd.

Duration

Period

Chart Shenzhen Kangtai Biological Products Co., Ltd.

More charts

Shenzhen Kangtai Biological Products Co. specialises in the research, development and marketing of human vaccines. Products include vaccines against hepatitis B, haemophilus influenzae type B, measles and rubella.

Sector

Pharmaceuticals

Calendar

2024-04-22 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Shenzhen Kangtai Biological Products Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

19.88 CNY

Average target price

37.75 CNY

Spread / Average Target

+89.89%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.	-26.78%	3.1B
CSL LIMITED	-2.68%	85.68B
SAMSUNG BIOLOGICS CO.,LTD.	+4.08%	41.4B
BIOGEN INC.	-25.35%	28.22B
UCB	+54.31%	24.64B
BIOMARIN PHARMACEUTICAL INC.	-4.52%	16.98B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.09%	13.29B
INCYTE CORPORATION	-17.77%	11.66B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.10%	11.65B
SWEDISH ORPHAN BIOVITRUM AB	+0.75%	8.18B

Biopharmaceuticals